WHO ICTRP trial
A phase II study combining gemcitabine and carboplatin in patients with…
JPRN-UMIN000019225 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000019225 |
|---|---|
| Public title | A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer |
| Scientific title | A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer - A phase II study combining gemcitabine and carboplatin in patients with platinum-resistant ovarian cancer |
| Primary sponsor | Osaka medical coledge |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | patients with platinum-resistant ovarian cancer |
| Interventions | We choice the combination of gemcitabine and carboplatin as the regimen of chemotherapy in platinum-resistant ovarian cancer. We throw the chemotherapy once per 3 weeks. Day1: gemcitabine 800mg/m2+Carboplatin AUC=4 Day8: gemcitabine… |
| Registration date | May 10, 2015 |
| Target size | 30 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: